Background: Mesenchymal stem cells (MSC) as targeted carriers for delivery of cancer drugs to tumor tissue. MSCs modulate the immune system through reprogramming T lymphocytes or stimulating natural killer (NK) cell to enhance the detection and destruction of cancer cells. These strategies, combined with genetic engineering and genome-editing techniques such as CRISPR/Cas9. Methods: In this review, various therapeutic aspects of MSCs in solid tumors, such as breast, pancreatic, and colorectal cancer are examined. We have summarized the emerging relationships between MSCs and their effects on tumorigenesis and development. Results: Positive outcomes of MSC therapy are significantly related to the substances released by MSCs, especially exosomes. Research indicates that extracellular vesicles (EVs) originating from mesenchymal stem cells (MSCs) are membrane-bound, these vesicles have the capability to imitate their source cells, exhibiting anti-tumor properties, along with a natural tendency to target tumors. Consequently, EVs derived from MSCs could be a promising cell-free option for cancer therapy. Conclusion: MSCs can be used to counteract the suppression of blood vessel formation in tumor tissues and thus prevent tumor progression.
